Therapeutic Antibodies

#Antibodies #Biotherapeutics #Drug discovery #Drug targets #Genovac

Berkeley Lights: Improving antibody discovery

John Proctor, Senior Vice President of Antibody Therapeutics at Berkeley Lights, and Brian Walters, President/CEO of Genovac Antibody Discovery, talk with DDW’s Megan Thomas about the company’s new Beacon system, which the CRO believes may be the new gold standard in antibody discovery with the potential to up antibody discovery. Read More

#Editor's Choice #Exclusive Content #News

#Antibodies #Covid-19 #Research

Critically ill Covid-19 patients have normal antibody production

Researchers at Lawson Health Research Institute (Lawson) and Western University have teamed up with local biotech company, Diagnostics Biochem Canada, to better understand Covid-19 and the body’s immune response to the infection. A recently published study followed 28 critically ill patients at London Health Sciences Centre (LHSC); 14 who tested… Read More

#Covid-19 #News

#Biologics #Clinical trials #Crohn's disease

Study of biologic therapies for moderate to severe Crohn’s Disease

The Janssen Pharmaceutical Companies of Johnson & Johnson has released efficacy and safety data for STELARA (ustekinumab) in Crohn’s disease (CD) and ulcerative colitis (UC), including data from the SEAVUE study, the first study of biologic therapies in patients with CD, presented in a Clinical Science Late-Breaking Abstract Plenary session. Read More

#News

#Antibodies #Cell therapy #Drug design #Drug technology #Protein Fluidics #Software

Updated platform helps streamline workflows

Sphere Fluidics has enhanced the capability and performance of its Cyto-Mine System. This is an automated platform which integrates single cell screening, sorting, dispensing, imaging and clone verification. The simplified design should help streamline workflows, reduce costs, increase throughput, and enable high-value clones to be captured in a single run. Read More

#News

#Antibodies #Awards #Biologics / Biotechnology #Drug development #Oncology #Therapeutics

Matwin spotlights innovation in the fight against cancer

Matwin has picked four companies that will now receive investment from the French oncology accelerator. This was during the MEET2WIN European Oncology Partnering Convention. Step Pharma was awarded ‘First-in-class therapeutic innovation’. The startup’s lead program (STP938) is based on a novel class of oral nucleotide synthesis inhibitors that target CTPS1… Read More

#News

#Antibodies #Cancer research #Drug development #Research

Flow Eighteen38 reagent antibodies licensed for cancer research

Flow Eighteen38, FairJourney Biologics (FJB) and the Hubrecht Institute are working together to harness the potential of FJB’s proprietary llama naïve libraries to develop antibodies for research tools for the group Hans Clevers. The Clevers group is studying molecular mechanisms of tissue development and cancer of various organs using organoids… Read More

#News

#Alzheimer's #Biologics

C. elegans: a natural model for developing therapies to slow ageing

Ageing is a complex and heterogeneous process and is best studied using natural models of ageing in whole organisms and large test populations. C. elegans is a proven model in many fields of biology including ageing, where major breakthroughs have occurred by identifying mutants and interventions that increase… Read More

#News #Videos

#Antigen #Drug discovery #Immunology / Virology & Vaccines #Monoclonal antibodies

How to get your drug to market faster

The pressure to take your drug to market faster is increasing. To achieve a successful journey to the first clinical trial phase in the fastest time possible, Eppendorf has identified three key elements that it is addressing in an eBook.  Comply with audit requirements and relevant certifications  Drive process efficiencies… Read More

#Editor's Choice #News

#Bioban #Biologics #Covid-19 #Life sciences #Thermo Fisher Scientific

Reforming biobanks: from siloes to collaborative powerhouses

By Erik Steinfelder, Biobanking Market Development Director at Thermo Fisher Scientific From hidden repositories, secreted deep in the basements of universities and hospitals, to the emergence of collaborative powerhouses driving ground-breaking therapies, biobanks have come a long way in the past 30 years. Biobanks were originally created as vast repositories… Read More

#Covid-19 #Exclusive Content #News

#Antibodies #Cell therapy #DNA #Drug delivery #Drug development #Drug discovery #Sequencing

Accelerating antibody discovery by making sequence space accessible

The biggest constraint in discovering new antibodies for immunotherapy is constructing the underlying DNA sequence, says Dr. Aaron Sato, CSO of Twist Bioscience. Inside the human body, the immune system generates antibodies that can target just about any foreign molecule. It does so through DNA recombination and somatic hypermutation –… Read More

#Editor's Choice #Exclusive Content #News

#Biologics #Cell / tissue culture #Covid-19 #Vaccines

Biden administration unblocks access to federal funded fetal tissue cells

A notice released by the US National Institutes of Health (NIH) on April 16, 2021 revealed that the Biden administration has reversed restrictions set in 2019 by the Trump administration on federal funding for medical research and biomedical studies by government employees using human fetal tissue from elective abortions. Health.com… Read More

#News

#Antibodies #Assays #Pharmaceuticals #Small molecules

Synthesising new solutions for small molecule antibodies

Toni Rogers and David Bunka, Aptamer Group discuss how newer antibody alternative technologies are demonstrating significant developments, offering novel solutions to improve success, decrease project timelines and produce innovative low-cost assays to small molecule targets across many sectors. Small molecules are ubiquitous in our environment, from toxins and heavy metals… Read More

#Editor's Choice #Exclusive Content #News

#Biologics #Covid-19 #Drug delivery #Gene therapy #Genetics / genomes #Immunology / Virology & Vaccines #RNA

The challenge of providing rapid, effective protection against Covid-19

Lisa Osborne, CEO at RANA Healthcare Solutions interviews Daniel Kavanagh, PhD, Senior Scientific Advisor, Gene Therapy at WCG. The Covid-19 pandemic has put vaccine development centre-stage. Never have citizens around the world been so focused on the length of time it takes to develop, test, approve, manufacture and distribute new… Read More

#Covid-19 #Exclusive Content #News

#Antibodies #Covid-19 #Drug development #Drug discovery #Therapies #Vaccines

Covid-19 response speed sets a new standard in drug discovery

    This paid-for advertorial by Berkeley Lights appeared in DDW Volume 22, Issue 2 – Spring 2021 The Covid-19 pandemic has illuminated how a coordinated response to infectious diseases can result in the development and commercialisation of novel vaccines and therapies at record pace. Several therapeutic antibodies and… Read More

#Covid-19 #Exclusive Content

#Antibodies #Clinical trial #Covid-19 #Immunology / Virology & Vaccines

Trial begins of antibody to treat Covid-19 respiratory disease

A clinical trial testing the safety and efficacy of an investigational monoclonal antibody for treating people who are hospitalised with respiratory disease and low blood oxygen due to infection with SARS-CoV-2, the virus that causes Covid-19, has begun. The Phase II trial, called the Covid-19 anti-CD14 Treatment Trial (CaTT), is… Read More

#Covid-19 #News

#Antibodies #Immune system #Vaccine candidate #Vaccines

How a soccer ball and a computer inform new vaccines

RSV is a complicated virus, and traditional vaccine methods have not worked. But UW’s Institute for Protein Design may have solved the problem using computational design. With the help of an innovative computer program, Icosavax has constructed virus-like particles (VLPs) using a two-part assembly (like a soccer ball). Adam Simpson,… Read More

#Editor's Choice #Exclusive Content #Intelligence #News #Opinion #Start-up Zone